STOCKS TELEGRAPH

Tag: KALA

  • 3 Stocks Making Headlines Today: Cardiol Therapeutics (CRDL), Kala Bio (KALA), Pelthos Therapeutics (PTHS)

    3 Stocks Making Headlines Today: Cardiol Therapeutics (CRDL), Kala Bio (KALA), Pelthos Therapeutics (PTHS)

    Biotechnology stocks continue attracting investor attention as companies across the healthcare sector advance clinical programs, strengthen balance sheets, and pursue strategic growth opportunities. Development-stage firms in particular remain closely watched for regulatory progress, trial execution, and investor engagement that could influence future valuation and long-term market positioning.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to strengthen its visibility within the biotech investment community as the company advances multiple cardiovascular development programs. Participation in high-profile investor conferences can play an important role for clinical-stage biotech firms by increasing institutional awareness and providing updates on strategic priorities and pipeline progress.

    Market Momentum

    As of May 14, 2026, CRDL closed at $1.37, up 0.74%, with trading volume of 531,499 shares compared to an average volume of 684,106 shares. The company currently maintains a market capitalization of $153.002M and a beta of 0.43, reflecting relatively moderate volatility for a development-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.36 highlights substantial upside potential tied to future clinical and regulatory developments.

    Investor and Corporate Visibility

    Cardiol recently announced that management will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026. Investor conferences often serve as important platforms for biotech companies to communicate clinical progress, development timelines, and long-term strategic priorities directly to institutional investors and industry participants.

    Clinical Execution

    The company continues advancing its Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis, with enrollment already surpassing 75% of participants. Earlier Phase II findings demonstrated reductions in pain, inflammation, and recurrence frequency, helping support the ongoing late-stage development program.

    Outlook

    With increasing investor engagement, ongoing late-stage clinical execution, and growing visibility within the biotechnology sector, Cardiol appears well-positioned to maintain market attention as it approaches future clinical and strategic milestones.

    Kala Bio Inc (KALA)

    Kala Bio Inc (NASDAQ: KALA) started the day on May 14, 2026, with a price increase of 0.98% at $3.09. During the day, the stock rose to $3.12 and sank to $2.87. Taking a long-term approach, KALA posted a 52-week range of $2.85-$1030.00.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 49.38%. Meanwhile, its Annual Earnings per share during the time was 49.38%.  This publicly-traded company’s shares outstanding now amount to $18.59 million, simultaneously with a float of $18.56 million. The organization now has a market capitalization of $57.44 million.

    Pelthos Therapeutics Inc (PTHS)

    As of May 14, 2026, Pelthos Therapeutics Inc (NYSEAMERICAN: PTHS) got off with the flyer as it spiked 6.46% to $27.69. During the day, the stock rose to $27.69 and sank to $25.75. Taking a long-term approach, PTHS posted a 52-week range of $9.00-$54.29.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -82.26%. Meanwhile, its Annual Earnings per share during the time were -82.26%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 56.34%. This publicly-traded company’s shares outstanding now amount to $3.37 million, simultaneously with a float of $2.73 million. The organization now has a market capitalization of $92.91 million.

  • Kala Pharmaceuticals, Inc. (KALA) Stock Losing Momentum After Hours, Here’s What’s Going on.

    Kala Pharmaceuticals, Inc. (KALA) Stock Losing Momentum After Hours, Here’s What’s Going on.

    Kala Pharmaceuticals, Inc. (KALA) is a clinical-stage biotherapeutics company engaged in the manufacturing and marketing of novel therapeutics for corneal disorders. Its AMPPLIFY mucus-penetrating particle Drug Delivery Technology is used for ocular therapeutics including EYSUVIS and INVELTYS for treating dry eyes disease and post-operative pain respectively. The company also has multiple pipeline projects including KPI-012 and others.

    The price of KALA stock in the regular trading on March 8, 2022, with an increase of 88.4% was $1.15. Its price declined by 2.61% at the last check of the aftermarket trading.

    KALA: Events and Happenings

    On March 08, 2022, KALA reported that UnitedHealthcare added EYSUVIS 0.25% as a covered brand on its marketed prescriptions with effect from March 2022. EYSUVIS has coverage for up to 70% of all marketing lives. Also, the company updated that Cigna Medicare added EYSUVIS as a favored brand with effect from February 2022.

    On February 18, 2022, KALA announced the grant of inducement award of non-statutory stock options to its employee outside its 2017 Equity Incentive Plan in agreement with NASDAQ Listing Rules. It granted stock options to acquire a sum of 15,000 shares of its common stock. The exercise price of the option award was $0.77 per share.

    KALA: Key Financials

    On November 15, 2021, KALA released its consolidated financial statement for the third fiscal quarter of 2021 ended September 30, 2021. Some of the focal highlights are cited below.

    Revenue

    Net product revenue in the third quarter of 2021 was $3.1 million as compared to $2.2 million for the corresponding quarter of 2020. The company gained $0.84 million in its net product revenue over the year. The company missed the revenue estimations by $2.09 million

    EPS

    Basic and diluted net loss in Q3 2021 was $28.1 million or $0.43 per share corresponding to $27.9 million or $0.50 for the same quarter of 2020. The company reported a slight gain in EPS over the year. The company’s EPS was in-line with the estimations.

    On November 15, 2021, KALA informed the press about the Combangio, Inc., acquisition for the development of CMB-012 or KPI-012. The product is used to treat wound healing in the persistent corneal epithelial defect. On November 11, 2021, KALA reported its Executive management’s participation at the following investor conferences

    • Jefferies London Healthcare Virtual Conference held on November 18, 2021, and
    • Virtual Ophthalmology Day at BTIG is held on November 30, 2021.

    Conclusion

    KALA stock declined 84% over the past year, the reason being the economic crisis in the pandemic. The company’s stock gained momentum in Tuesday’s regular trading after it announced coverage of EUSUVIS by the two reputed healthcare companies. Afterwards, it lost the momentum to shed its gain. For the upcoming earnings release, the company’s revenue guidance is $3.41 million and EPS guidance is -$0.38.